← Compound index
RESEARCH FAMILY / CPG-GZK-111

CPG & GZK-111ЦПГ / ГЗК-111

Cycloprolylglycine (CPG) is a naturally occurring cyclic dipeptide formed from proline and glycine. GZK-111 is an experimental linear precursor. CPG has also been measured as a metabolite of Noopept.

CognitionStressRecovery
Source linked

What the studies found

Animal research · 2018

Pharmacokinetics of Noopept and its active metabolite cycloprolylglycine in rats

Findings for this preparation

After Noopept administration in rats, researchers detected its metabolite cycloprolylglycine in plasma and brain. Its pharmacokinetic profile differed from that of Noopept. This experiment measured CPG after exposure to the parent compound.

Study notes · methods, sources and limitations

Participants or model Rat plasma and brain pharmacokinetic study.

Important limitations

  • Animal metabolite kinetics do not establish human exposure, cognitive benefit or a dosing interval.

Biomeditsinskaya Khimiya. 2018;64(5):455–458. · Journal publication

Original source or citation ↗

Study results and tables ↗

Biomarker study in people · no treatment tested · 2019

Plasma cyclic glycine proline/IGF-1 ratio predicts clinical outcome and recovery in stroke patients.

Naturally occurring CPG measured in blood; no CPG treatment given

Biomarker association
Lower baseline cGP and cGP/IGF-1 ratio in stroke; baseline ratio correlated with day-90 NIHSS and its changeNo correlation coefficient or absolute concentration in the indexed abstract

In 34 stroke patients, baseline cyclic glycine-proline/IGF-1 ratio was associated with later neurological recovery. Patients were not treated with cGP; this was a biomarker study.

Study notes · methods, sources and limitations

Participants or model 34 stroke patients recruited within three days; 50 age-matched controls

Design 34 patients recruited within 3 days of stroke; 50 age-matched controls without stroke.

Participants
34 stroke patients; 50 controls
Assessment schedule
Baseline within 3 days; days 7 and 90

Important limitations

  • Observational association is not evidence that CPG administration improves stroke recovery. Small cohort; causal interpretation and external predictive validity remain unresolved. Indexed abstract checked; complete methods, tables and independent replication have not been appraised.
  • An association with endogenous cGP does not show that giving cGP or GZK-111 improves recovery.

Annals of clinical and translational neurology (2019); PMID 31019991 · Indexed abstract

Original source or citation ↗

Study results and tables ↗

Animal research · 2022

Metabolism of a New Dipeptide Neuroprotector in Rats.

Four GZK-111 biotransformation products were identified. Ester hydrolysis and pathways producing phenylacetic acid and CPG were described.

Study notes · methods, sources and limitations

Participants or model Rat plasma HPLC–mass spectrometry

Important limitations

  • Metabolite identification does not establish human pharmacokinetics, brain exposure or clinical equivalence to Noopept. Indexed abstract checked; complete methods, tables and independent replication have not been appraised.

Bulletin of experimental biology and medicine (2022); PMID 35352249 · Indexed abstract

Original source or citation ↗

Study results and tables ↗
01 / OVERVIEW

About CPG & GZK-111

Names in this research collection

CPG · CGP · Cycloprolylglycine · cyclo(Pro-Gly) · cyclo(Gly-Pro) · GZK-111 · pGlu-Asn-NH2

Research background

A grouped record for endogenous cyclo(Pro-Gly), its experimental linear precursor GZK-111 and the connection to Noopept metabolism.

Compound class
Peptide research family
Research collection
Neuropeptide research · editorial grouping
Institutions in linked studies
See individual study records
Source review
Review dates and the material assessed are listed with each publication below.
02 / HOW TO READ THE RESEARCH

Understanding the evidence

Human research

No human treatment trial assessed for this family

Study methods

Member-specific studies; patents and archival leads identified separately

Independent replication

Independent replication not established by the records collected here

Source access

Primary abstracts, selected full texts, patents and explicit retrieval targets

Safety evidence

Cell and animal effects do not establish human safety; analogues may differ

Open a topic for the evidence assessment.

More findings, background and history

CPG: mechanisms, metabolism and human observations

The 2025-volume review, published online in January 2026 brings together the AMPA/neurotrophin and IGF-1 research programs. These are proposed mechanisms supported by different experimental systems, not an established combined clinical pathway.

The GZK-111 rat pharmacokinetic study reported CPG plasma concentrations 50–70 times those of the parent compound and circulation lasting more than twice as long. This does not establish human exposure or brain delivery.

In the 34-patient stroke cohort, cGP/IGF-1 was measured as a prognostic marker. No CPG treatment was given. The 2002 coagulation experiments are a separate preclinical finding; they do not establish prevention of stroke or bleeding safety.

IDENTITY / MEMBER-SPECIFIC EVIDENCE

Inside this research family

Grouping supports navigation. It does not imply equivalent composition, mechanisms, effectiveness or safety.

Research objects, findings and source boundaries
MemberIdentityWhat the source supports
CPGCyclic Pro-Gly dipeptide

Identified in rat brain; AMPA/TrkB experiments and a separate IGF-1/IGFBP-3 program investigate different mechanisms. A human stroke cohort measured biomarkers, not treatment response.

Identification of a novel endogenous memory facilitating cyclic dipeptide cyclo-prolylglycine in rat brain. ↗

Neuropeptide cycloprolylglycine is an endogenous positive modulator of AMPA receptors. ↗

Neuroprotective Effect of the Neuropeptide Cycloprolylglycine Depends on AMPA- and TrkB-Receptor Activation. ↗

Neuropeptide Cyclo-Prolylglycine: Discovery, Pharmacological Effects, and Mechanism of Action ↗

Cyclic glycine-proline regulates IGF-1 homeostasis by altering the binding of IGFBP-3 to IGF-1. ↗

Plasma cyclic glycine proline/IGF-1 ratio predicts clinical outcome and recovery in stroke patients. ↗

[Multicomponent antithrombotic effect of the neuroprotective prolyl dipeptide GVS-111 and its major metabolite cyclo-L-prolylglycine]. ↗

GZK-111N-phenylacetyl-Gly-Pro ethyl ester

Rat pharmacokinetics support conversion to CPG; human pharmacokinetics remain unestablished here.

Preclinical Pharmacokinetics of GZK-111, a Dipeptide with Neuroprotective Activity. ↗

Metabolism of a New Dipeptide Neuroprotector in Rats. ↗

Noopept / GVS-111N-phenylacetyl-Pro-Gly ethyl ester

Opposite linear residue order to GZK-111; a rat metabolism study supports CPG formation.

The major metabolite of dipeptide piracetam analogue GVS-111 in rat brain and its similarity to endogenous neuropeptide cyclo-L-prolylglycine. ↗

pGlu-Asn-NH₂Separate pyroglutamyl dipeptide branch

A piracetam-inspired compound studied in rat hippocampal plasticity; neither CPG nor a Noopept alias.

Pyroglutamyl-asparagine amide normalizes long-term potentiation in rat hippocampal slices. ↗

Interpretation and open questions

Endogenous presence is not evidence that increasing a peptide improves health.

GPE (Gly-Pro-Glu), the IGF-1-related branch, and non-Russian cyclic analogues are adjacent research targets. They are not assigned the outcomes of CPG.

Explore the Russian peptide research map ↗

Stroke research matrix ↗ — compare human stroke outcomes, experimental findings, safety and adjacent cerebral-ischemia research.

What remains unclear

The 34-patient cohort measured biomarkers. Coagulation methods, GZK-111 exposure in the brain and the full IGF-1 and AMPA experiments remain open questions.

Human reports are linked; their presence does not establish effectiveness. Several publications can describe the same participants.

Browse original study records ↗
PATENT RESEARCH / COLLECTION UPDATED 7 NOVEMBER 2026

Patents and claimed inventions

These 1 grouped records distinguish claimed molecules, uses, formulations and related chemistry. Patent disclosure does not establish clinical benefit or approval.

2018 · RU2646604C2 · GZK-111: N-phenylacetyl glyprolin derivativesMolecule · CPG formation observed during incubation with plasma and brain homogenate

Findings described in words

The disclosure reports conversion of GZK-111 to CPG and activity in selected preclinical models.

Metabolic identity
CPG formation observed during incubation with plasma and brain homogenateSupports a precursor/metabolite relationship; not a human clinical exposure estimate
Cell-injury comparison
Concentration-dependent neuroprotection reported for GZK-111 in the neuronal-cell modelNo quantitative cell-survival percentage independently transcribed
All reported results, comparisons and limitations →

Molecule. The claimed class includes phenylacetylglycyl-L-proline ethyl ester, alongside other stereochemical and terminal variants.

The precursor and cyclic metabolite CPG are different molecules. A broad class is not a patent match to every glyprolin or to the similarly named GZS-411.

Publication
RU2646604C2 ↗ · 2018-03-06
Earliest priority / filing
2016-01-12 / 2016-01-12
Original applicant / assignee
Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова"
Indexed status
Not shown; official status unverified · checked 2026-11-06
Patent family
59497169 · family publications are related filings, not independent studies.
Original title, inventors and related publications

Novel glyprolins with nootropic, anti-hypoxic, neuroprotective and anssiylitis activity

Inventors: Сергей Борисович Середенин; Татьяна Александровна Гудашева; Ксения Николаевна Колясникова; Елена Александровна Кузнецова; Татьяна Александровна Воронина; Милада Альнордовна Яркова; Татьяна Алексеевна Антипова; Светлана Александровна Литвинова; Николай Николаевич Золотов.

RU2646604C2

Original patent PDF ↗

Read source review →

Status is an indexed snapshot, not an official legal assessment. Search the patent collection and read the method →

03 / SOURCE RECORDS

Findings by study

Explore related research ↗

Experiment described in a patent · 2018

GZK-111: N-phenylacetyl glyprolin derivatives — RU2646604C2

The disclosure reports conversion of GZK-111 to CPG and activity in selected preclinical models.

Study notes and original source
2018Patent / reported experimentsFull text available

GZK-111: N-phenylacetyl glyprolin derivatives — RU2646604C2

Patent-defined substance or composition · Patent publication

Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.

Сергей Борисович Середенин, Татьяна Александровна Гудашева, Ксения Николаевна Колясникова, Елена Александровна Кузнецова, Татьяна Александровна Воронина, Милада Альнордовна Яркова, Татьяна Алексеевна Антипова, Светлана Александровна Литвинова, Николай Николаевич Золотов · RU2646604C2 · patent family 59497169

The disclosure reports conversion of GZK-111 to CPG and activity in selected preclinical models.

Results and tables

Reported patent results

Findings described in words

The disclosure reports conversion of GZK-111 to CPG and activity in selected preclinical models.

GZK-111/GZK-113 experimental program: metabolism assays, neuronal-cell injury and animal behavioral/hypoxia tests.

Population or model GZK-111/GZK-113 experimental program: metabolism assays, neuronal-cell injury and animal behavioral/hypoxia tests.

Results · Experimental metabolism, cell-injury and behavioral/hypoxia summaries.
MeasureResultComparison, timing and statistics
Metabolic identityCPG formation observed during incubation with plasma and brain homogenateSupports a precursor/metabolite relationship; not a human clinical exposure estimate
Cell-injury comparisonConcentration-dependent neuroprotection reported for GZK-111 in the neuronal-cell modelNo quantitative cell-survival percentage independently transcribed
Animal findingsIncreased survival time under experimental hypoxia and anxiolytic-like behavioral findings reported at selected exposuresDifferent compounds and assays must not be pooled

These results do not establish human cognition or anxiety treatment and cannot be transferred to GZS-411. GZK-111 is distinct from its cyclic metabolite CPG.

Source for these results ↗ · Reviewed 2026-11-06

Population / setting
GZK-111/GZK-113 experimental program: metabolism assays, neuronal-cell injury and animal behavioral/hypoxia tests.
Source reviewed
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
  • The precursor and cyclic metabolite CPG are different molecules. A broad class is not a patent match to every glyprolin or to the similarly named GZS-411.
  • These results do not establish human cognition or anxiety treatment and cannot be transferred to GZS-411. GZK-111 is distinct from its cyclic metabolite CPG.
  • Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
  • Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.

Reviewed 2026-11-06.

Read the source ↗

Animal research · 2018

Pharmacokinetics of Noopept and its active metabolite cycloprolylglycine in rats

After Noopept administration in rats, researchers detected its metabolite cycloprolylglycine in plasma and brain. Its pharmacokinetic profile differed from that of Noopept. This experiment measured CPG after exposure to the parent compound.

Study notes and original source
2018Animal / experimentalEnglish abstract

Pharmacokinetics of Noopept and its active metabolite cycloprolylglycine in rats

· Journal publication

S. S. Boyko, V. P. Zherdev, R. V. Shevchenko · Biomeditsinskaya Khimiya. 2018;64(5):455–458.

Cycloprolylglycine was found in rat plasma and brain and had a pharmacokinetic profile different from the parent drug. The paper relates these findings to memory-associated pharmacology.

Population / setting
Rat plasma and brain pharmacokinetic study.
Source reviewed
Primary PubMed abstract and bibliographic metadata checked; full concentration-time tables not reviewed.
Study limitations
  • Animal metabolite kinetics do not establish human exposure, cognitive benefit or a dosing interval.

Reviewed 2026-11-01.

Read the source ↗

Animal research · 2022

Metabolism of a New Dipeptide Neuroprotector in Rats.

Four GZK-111 biotransformation products were identified. Ester hydrolysis and pathways producing phenylacetic acid and CPG were described.

Study notes and original source
2022Animal / experimentalEnglish abstract

Metabolism of a New Dipeptide Neuroprotector in Rats.

Kolyvanov GB, Bochkov PO, Litvin AA, Shevchenko RV, Podol'ko AL, Kravtsova OY, Kolyasnikova KN, Zherdev VP · Bulletin of experimental biology and medicine (2022); PMID 35352249

Four GZK-111 biotransformation products were identified. Ester hydrolysis and pathways producing phenylacetic acid and CPG were described.

Population / setting
Rat plasma HPLC–mass spectrometry
Source reviewed
Original publication metadata and indexed abstract checked via Europe PMC; no full-text appraisal.
Study limitations
  • Metabolite identification does not establish human pharmacokinetics, brain exposure or clinical equivalence to Noopept.
  • Indexed abstract checked; complete methods, tables and independent replication have not been appraised.

Reviewed 2026-10-17.

Read the source ↗

Biomarker study in people · no treatment tested · 2019

Plasma cyclic glycine proline/IGF-1 ratio predicts clinical outcome and recovery in stroke patients.

In 34 stroke patients, baseline cyclic glycine-proline/IGF-1 ratio was associated with later neurological recovery. Patients were not treated with cGP; this was a biomarker study.

Biomarker association · Lower baseline cGP and cGP/IGF-1 ratio in stroke; baseline ratio correlated with day-90 NIHSS and its change · No correlation coefficient or absolute concentration in the indexed abstract

Study notes and original source
2019Human study · design details unresolvedEnglish abstract

Plasma cyclic glycine proline/IGF-1 ratio predicts clinical outcome and recovery in stroke patients.

Fan D, Krishnamurthi R, Harris P, Barber PA, Guan J · Annals of clinical and translational neurology (2019); PMID 31019991

In 34 stroke patients, baseline cyclic glycine-proline/IGF-1 ratio was associated with later neurological recovery. Patients were not treated with cGP; this was a biomarker study.

Results and tables

Reported findings and study design

In 34 stroke patients, baseline cyclic glycine-proline/IGF-1 ratio was associated with later neurological recovery. Patients were not treated with cGP; this was a biomarker study.

34 patients recruited within 3 days of stroke; 50 age-matched controls without stroke.

Results · Primary-publication indexed abstract; no full-text table appraisal
MeasureResultComparison, timing and statistics
Biomarker associationLower baseline cGP and cGP/IGF-1 ratio in stroke; baseline ratio correlated with day-90 NIHSS and its changeNo correlation coefficient or absolute concentration in the indexed abstract
Participants34 stroke patients; 50 controls
Assessment scheduleBaseline within 3 days; days 7 and 90

An association with endogenous cGP does not show that giving cGP or GZK-111 improves recovery.

Source for these results ↗ · Reviewed 2026-11-01

Population / setting
34 stroke patients recruited within three days; 50 age-matched controls
Source reviewed
Original publication metadata and indexed abstract checked via Europe PMC; no full-text appraisal.
Study limitations
  • Observational association is not evidence that CPG administration improves stroke recovery. Small cohort; causal interpretation and external predictive validity remain unresolved.
  • Indexed abstract checked; complete methods, tables and independent replication have not been appraised.

Reviewed 2026-11-01.

Read the source ↗

Animal research · 2014

Cyclic glycine-proline regulates IGF-1 homeostasis by altering the binding of IGFBP-3 to IGF-1.

The investigators reported context-dependent modulation of IGF-1 activity and modeled altered binding to IGFBP-3. Animal experiments reported improved ischemic recovery and inhibited lymphoma growth.

Study notes and original source
2014Animal / experimentalEnglish abstract

Cyclic glycine-proline regulates IGF-1 homeostasis by altering the binding of IGFBP-3 to IGF-1.

Guan J, Gluckman P, Yang P, Krissansen G, Sun X, Zhou Y, Wen J, Phillips G, Shorten PR, McMahon CD, Wake GC, Chan WH, Thomas MF, Ren A, Moon S, Liu DX · Scientific reports (2014); PMID 24633053

The investigators reported context-dependent modulation of IGF-1 activity and modeled altered binding to IGFBP-3. Animal experiments reported improved ischemic recovery and inhibited lymphoma growth.

Population / setting
Cell culture, mathematical modeling, rat ischemic brain injury and mouse tumor experiments
Source reviewed
Original publication metadata and indexed abstract checked via Europe PMC; no full-text appraisal.
Study limitations
  • Multiple experimental systems do not establish a clinical mechanism or treatment benefit. The IGF-1 measurements and the Russian AMPA/TrkB experiments address different pathways.
  • Indexed abstract checked; complete methods, tables and independent replication have not been appraised.

Reviewed 2026-10-17.

Read the source ↗

Animal research · 2002

[Multicomponent antithrombotic effect of the neuroprotective prolyl dipeptide GVS-111 and its major metabolite cyclo-L-prolylglycine].

GVS-111 altered coagulation and fibrinolysis in experimental work. In-vitro CPG also showed antiaggregant activity; concentrations extending to 10⁻¹⁰ M were reported.

Study notes and original source
2002Animal / experimentalEnglish abstract

[Multicomponent antithrombotic effect of the neuroprotective prolyl dipeptide GVS-111 and its major metabolite cyclo-L-prolylglycine].

Ostrovskaia RU, Liapina LA, Pastorova VE, Mirzoev TKh, Gudasheva TA, Seredenin SB, Ashmarin IP · Eksperimental'naia i klinicheskaia farmakologiia (2002); PMID 12109290

GVS-111 altered coagulation and fibrinolysis in experimental work. In-vitro CPG also showed antiaggregant activity; concentrations extending to 10⁻¹⁰ M were reported.

Population / setting
In-vivo GVS-111 experiments and in-vitro coagulation assays
Source reviewed
Original publication metadata and indexed abstract checked via Europe PMC; no full-text appraisal.
Study limitations
  • The in-vivo regimen was for GVS-111, not CPG. Laboratory coagulation findings do not establish stroke prevention, bleeding safety or a human dose.
  • Indexed abstract checked; complete methods, tables and independent replication have not been appraised.

Reviewed 2026-10-17.

Read the source ↗

Review of earlier studies · 2023

Cyclic Glycine-Proline (cGP) Normalises Insulin-Like Growth Factor-1 (IGF-1) Function: Clinical Significance in the Ageing Brain and in Age-Related Neurological Conditions.

The review brings together cGP/IGF-1 associations and experimental intervention studies. Its stroke biomarker discussion includes the separately listed 2019 cohort.

Study notes and original source
2023ReviewEnglish abstract

Cyclic Glycine-Proline (cGP) Normalises Insulin-Like Growth Factor-1 (IGF-1) Function: Clinical Significance in the Ageing Brain and in Age-Related Neurological Conditions.

Guan J, Li F, Kang D, Anderson T, Pitcher T, Dalrymple-Alford J, Shorten P, Singh-Mallah G · Molecules (Basel, Switzerland) (2023); PMID 36770687

The review brings together cGP/IGF-1 associations and experimental intervention studies. Its stroke biomarker discussion includes the separately listed 2019 cohort.

Population / setting
Narrative review of experimental and clinical biomarker research
Source reviewed
Original publication metadata and indexed abstract checked via Europe PMC; no full-text appraisal.
Study limitations
  • Review synthesis is not an independent trial. The human studies report associations. The treatment experiments were in animals.
  • Indexed abstract checked; complete methods, tables and independent replication have not been appraised.

Reviewed 2026-10-17.

Read the source ↗

Review of earlier studies · 2025

Neuropeptide Cyclo-Prolylglycine: Discovery, Pharmacological Effects, and Mechanism of Action

The authors discuss two proposed mechanisms: IGF-1 homeostasis and AMPA modulation with downstream neurotrophin signaling. The review connects the endogenous peptide with the Noopept research lineage.

Study notes and original source
2025ReviewEnglish abstract

Neuropeptide Cyclo-Prolylglycine: Discovery, Pharmacological Effects, and Mechanism of Action

T. A. Gudasheva, K. N. Koliasnikova, A. G. Alyaeva, P. Yu. Povarnina · Neurochemical Journal 19:549–556 (2025); published online 13 January 2026

The authors discuss two proposed mechanisms: IGF-1 homeostasis and AMPA modulation with downstream neurotrophin signaling. The review connects the endogenous peptide with the Noopept research lineage.

Population / setting
Narrative synthesis of CPG research
Source reviewed
Primary publisher abstract, publication dates and references checked.
Study limitations
  • A synthesis of earlier studies, not a new efficacy trial or independent replication.
  • Publisher abstract and references checked; subscription full text not reviewed.

Reviewed 2026-10-17.

Read the source ↗

Animal research · 2022

Preclinical Pharmacokinetics of GZK-111, a Dipeptide with Neuroprotective Activity.

GZK-111 underwent extensive conversion to CPG in rats. CPG persisted more than twice as long in plasma and reached higher concentrations than the parent compound.

Study notes and original source
2022Animal / experimentalEnglish abstract

Preclinical Pharmacokinetics of GZK-111, a Dipeptide with Neuroprotective Activity.

Litvin AA, Kolyvanov GB, Bochkov PO, Shevchenko RV, Podol'ko AL, Kolyasnikova KN, Zherdev VP · Bulletin of experimental biology and medicine

GZK-111 underwent extensive conversion to CPG in rats. CPG persisted more than twice as long in plasma and reached higher concentrations than the parent compound.

Population / setting
Rats; intravenous and intragastric pharmacokinetics
Source reviewed
Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Study limitations
  • Preclinical findings do not establish human benefit or safety.
  • Abstract only. Full methods and independent replication remain unconfirmed.

Reviewed 2026-10-05.

Read the source ↗

Laboratory analysis · 1996

Identification of a novel endogenous memory facilitating cyclic dipeptide cyclo-prolylglycine in rat brain.

Chromatographic and mass-spectrometric methods identified CPG in rat brain. Synthetic CPG also altered passive-avoidance performance in rats. Endogenous detection does not establish supplementation benefit.

Endogenous brain CPG content · 2.8 ± 0.3 nmol/g wet brain

Study notes and original source
1996Analytical / composition studyEnglish abstract

Identification of a novel endogenous memory facilitating cyclic dipeptide cyclo-prolylglycine in rat brain.

Gudasheva TA, Boyko SS, Akparov VKh, Ostrovskaya RU, Skoldinov SP, Rozantsev GG, Voronina TA, Zherdev VP, Seredenin SB · FEBS letters

Chromatographic and mass-spectrometric methods identified CPG in rat brain. Synthetic CPG also altered passive-avoidance performance in rats. Endogenous detection does not establish supplementation benefit.

Results and tables

Reported findings and study design

Endogenous CPG detection in rat brain plus a rat passive-avoidance assay using synthetic CPG 0.1 mg/kg IP.

Population or model Rat brain extracts and rat behavioral experiments

Results · Previously retrieved indexed abstract; numerical statements checked against the saved source text
MeasureResultComparison, timing and statistics
Endogenous brain CPG content2.8 ± 0.3 nmol/g wet brain
Antiamnesic responseReported at 0.1 mg/kgNo numerical behavioral effect size supplied

Values describe this study and its comparison. Unreported effect sizes and missing denominators have not been inferred.

Source for these results ↗ · Reviewed 2026-10-29

Population / setting
Rat brain extracts and rat behavioral experiments
Source reviewed
Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Study limitations
  • Preclinical findings do not establish human benefit or safety.
  • Abstract only. Full methods and independent replication remain unconfirmed.

Reviewed 2026-10-05.

Read the source ↗

Animal research · 1997

The major metabolite of dipeptide piracetam analogue GVS-111 in rat brain and its similarity to endogenous neuropeptide cyclo-L-prolylglycine.

Rat-brain CPG increased approximately 2.5-fold one hour after GVS-111 administration. Enzyme experiments supported conversion to CPG; these findings do not prove that CPG accounts for every Noopept effect.

Study notes and original source
1997Animal / experimentalEnglish abstract

The major metabolite of dipeptide piracetam analogue GVS-111 in rat brain and its similarity to endogenous neuropeptide cyclo-L-prolylglycine.

Gudasheva TA, Boyko SS, Ostrovskaya RU, Voronina TA, Akparov VK, Trofimov SS, Rozantsev GG, Skoldinov AP, Zherdev VP, Seredenin SB · European journal of drug metabolism and pharmacokinetics

Rat-brain CPG increased approximately 2.5-fold one hour after GVS-111 administration. Enzyme experiments supported conversion to CPG; these findings do not prove that CPG accounts for every Noopept effect.

Population / setting
Rat metabolism and enzyme preparations
Source reviewed
Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Study limitations
  • Preclinical findings do not establish human benefit or safety.
  • Abstract only. Full methods and independent replication remain unconfirmed.

Reviewed 2026-10-05.

Read the source ↗

Lab research · 2016

Neuropeptide cycloprolylglycine is an endogenous positive modulator of AMPA receptors.

CPG enhanced AMPA currents in rat cerebellar Purkinje cells. A proposed downstream BDNF mechanism requires distinction from the measured electrophysiological response.

Study notes and original source
2016In vitroEnglish abstract

Neuropeptide cycloprolylglycine is an endogenous positive modulator of AMPA receptors.

Gudasheva TA, Grigoriev VV, Koliasnikova KN, Zamoyski VL, Seredenin SB · Doklady. Biochemistry and biophysics

CPG enhanced AMPA currents in rat cerebellar Purkinje cells. A proposed downstream BDNF mechanism requires distinction from the measured electrophysiological response.

Population / setting
Rat Purkinje-cell electrophysiology
Source reviewed
Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Study limitations
  • Preclinical findings do not establish human benefit or safety.
  • Abstract only. Full methods and independent replication remain unconfirmed.

Reviewed 2026-10-05.

Read the source ↗

Lab research · 2022

Neuroprotective Effect of the Neuropeptide Cycloprolylglycine Depends on AMPA- and TrkB-Receptor Activation.

AMPA and Trk receptor blockers prevented the reported CPG neuroprotective effect in cultured-cell experiments. Pharmacological blockade supports pathway involvement, not a fully resolved mechanism.

Study notes and original source
2022In vitroEnglish abstract

Neuroprotective Effect of the Neuropeptide Cycloprolylglycine Depends on AMPA- and TrkB-Receptor Activation.

Gudasheva TA, Koliasnikova KN, Alyaeva AG, Nikolaev SV, Antipova TA, Seredenin SB · Doklady. Biochemistry and biophysics

AMPA and Trk receptor blockers prevented the reported CPG neuroprotective effect in cultured-cell experiments. Pharmacological blockade supports pathway involvement, not a fully resolved mechanism.

Population / setting
Cultured-cell injury and receptor-blockade experiments
Source reviewed
Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Study limitations
  • Preclinical findings do not establish human benefit or safety.
  • Abstract only. Full methods and independent replication remain unconfirmed.

Reviewed 2026-10-05.

Read the source ↗

Animal research · 2016

Neuropeptide Cycloprolylglycine Exhibits Neuroprotective Activity after Systemic Administration to Rats with Modeled Incomplete Global Ischemia and in In Vitro Modeled Glutamate Neurotoxicity.

CPG improved selected neurological and locomotor measures after incomplete global ischemia in rats and protected HT-22 cells against glutamate toxicity.

Study notes and original source
2016Animal / experimentalEnglish abstract

Neuropeptide Cycloprolylglycine Exhibits Neuroprotective Activity after Systemic Administration to Rats with Modeled Incomplete Global Ischemia and in In Vitro Modeled Glutamate Neurotoxicity.

Povarnina PY, Kolyasnikova KN, Nikolaev SV, Antipova TA, Gudasheva TA · Bulletin of experimental biology and medicine

CPG improved selected neurological and locomotor measures after incomplete global ischemia in rats and protected HT-22 cells against glutamate toxicity.

Population / setting
Rat ischemia model and HT-22 cells
Source reviewed
Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Study limitations
  • Preclinical findings do not establish human benefit or safety.
  • Abstract only. Full methods and independent replication remain unconfirmed.

Reviewed 2026-10-05.

Read the source ↗

Lab research · 2004

Pyroglutamyl-asparagine amide normalizes long-term potentiation in rat hippocampal slices.

Pyroglutamyl-asparagine amide facilitated weakly induced long-term potentiation and countered ethanol-impaired potentiation in rat hippocampal slices. This separate piracetam-inspired dipeptide is not CPG.

Study notes and original source
2004In vitroEnglish abstract

Pyroglutamyl-asparagine amide normalizes long-term potentiation in rat hippocampal slices.

Kapai NA, Chepkova AN, Gudasheva TA, Morozova AA, Skrebitskii VG · Bulletin of experimental biology and medicine

Pyroglutamyl-asparagine amide facilitated weakly induced long-term potentiation and countered ethanol-impaired potentiation in rat hippocampal slices. This separate piracetam-inspired dipeptide is not CPG.

Population / setting
Rat hippocampal slices
Source reviewed
Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Study limitations
  • Preclinical findings do not establish human benefit or safety.
  • Abstract only. Full methods and independent replication remain unconfirmed.

Reviewed 2026-10-05.

Read the source ↗

Review of earlier studies · 2018

Novel Technologies for Dipeptide Drugs Design and their Implantation.

The developers distinguish drug-inspired peptide design (Noopept and Dilept) from mimicking peptide/protein turns (GB-115 and GK-2). This is a historical design framework, not evidence of a shared clinical effect.

Study notes and original source
2018ReviewEnglish abstract

Novel Technologies for Dipeptide Drugs Design and their Implantation.

Gudasheva TA, Ostrovskaya RU, Seredenin SB · Current pharmaceutical design

The developers distinguish drug-inspired peptide design (Noopept and Dilept) from mimicking peptide/protein turns (GB-115 and GK-2). This is a historical design framework, not evidence of a shared clinical effect.

Population / setting
Developer account of medicinal-chemistry programs
Source reviewed
Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Study limitations
  • Developer review; claims require appraisal of each original study.
  • A shared design method does not establish equivalent biology or clinical benefit.

Reviewed 2026-10-05.

Read the source ↗

Follow shared publications or research classes. These links do not establish equivalent effects between compounds.

Research collection curated by @PepMariner · editorial standards. Send a source correction ↗

Browse bibliography & PDFs ↗